Back to Journals » Breast Cancer: Targets and Therapy » Volume 10

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer

Total article views   HTML views PDF downloads Totals
17,607 Dovepress* 8,576+ 1,299 9,875
PubMed Central* 9,031 667 9,698
Totals 17,607 1,966 19,573
*Since 4 May 2018
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar